CA3127767A1 - Monoclonal antibodies that specifically bind to the beta region of the trbv-9 family of the human t-cell receptor, and methods for their use - Google Patents

Monoclonal antibodies that specifically bind to the beta region of the trbv-9 family of the human t-cell receptor, and methods for their use Download PDF

Info

Publication number
CA3127767A1
CA3127767A1 CA3127767A CA3127767A CA3127767A1 CA 3127767 A1 CA3127767 A1 CA 3127767A1 CA 3127767 A CA3127767 A CA 3127767A CA 3127767 A CA3127767 A CA 3127767A CA 3127767 A1 CA3127767 A1 CA 3127767A1
Authority
CA
Canada
Prior art keywords
antibody
antigen
cell
amino acid
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3127767A
Other languages
English (en)
French (fr)
Inventor
Olga Vladimirovna Britanova
Dmitry Borisovich STAROVEROV
Anna Valentinovna EVSTRATEVA
Alexey Konstantinovich MISORIN
Timofey Aleksandrovich Nemankin
Mariia Aleksandrovna SHCHEMELEVA
Anna Konstantinovna VLADIMIROVA
Arina Vitalevna ANIKINA
Roman Alekseevich IVANOV
Dmitry Valentinovich MOROZOV
Pavel Andreevich IAKOVLEV
Sergey Anatolievich Lukyanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocad JSC
Original Assignee
Biocad JSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad JSC filed Critical Biocad JSC
Publication of CA3127767A1 publication Critical patent/CA3127767A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3127767A 2018-12-25 2019-12-24 Monoclonal antibodies that specifically bind to the beta region of the trbv-9 family of the human t-cell receptor, and methods for their use Pending CA3127767A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018146031A RU2712251C1 (ru) 2018-12-25 2018-12-25 Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
RU2018146031 2018-12-25
PCT/RU2019/050258 WO2020091635A2 (ru) 2018-12-25 2019-12-24 Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения

Publications (1)

Publication Number Publication Date
CA3127767A1 true CA3127767A1 (en) 2020-05-07

Family

ID=69184123

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3127767A Pending CA3127767A1 (en) 2018-12-25 2019-12-24 Monoclonal antibodies that specifically bind to the beta region of the trbv-9 family of the human t-cell receptor, and methods for their use
CA3124813A Pending CA3124813A1 (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human trbv9

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3124813A Pending CA3124813A1 (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human trbv9

Country Status (25)

Country Link
US (1) US12227572B2 (https=)
EP (1) EP3907239A4 (https=)
JP (1) JP2022532274A (https=)
KR (2) KR102788029B1 (https=)
CN (2) CN113646333B (https=)
AR (1) AR117734A1 (https=)
AU (1) AU2020204492A1 (https=)
BR (1) BR112021012555A2 (https=)
CA (2) CA3127767A1 (https=)
CL (1) CL2021001705A1 (https=)
CO (2) CO2021008218A2 (https=)
CR (1) CR20210354A (https=)
EA (1) EA202191813A1 (https=)
EC (1) ECSP21046333A (https=)
IL (1) IL284370A (https=)
JO (1) JOP20210169B1 (https=)
MA (1) MA53689B1 (https=)
MX (1) MX2021007719A (https=)
MY (1) MY205967A (https=)
PE (1) PE20220217A1 (https=)
PH (2) PH12021551775A1 (https=)
RU (1) RU2712251C1 (https=)
SG (1) SG11202106975VA (https=)
WO (2) WO2020091635A2 (https=)
ZA (1) ZA202104357B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514923B2 (en) 2017-12-25 2026-01-06 Joint Stock Company “Biocad” Methods of inhibiting the T cell receptor by administering a monoclonal antibody that binds TRBV9

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
CN116867519A (zh) * 2020-12-01 2023-10-10 约翰斯霍普金斯大学 治疗t细胞癌症的方法和材料
CN116510006A (zh) * 2022-01-31 2023-08-01 拜奥卡德联合股份公司 抗trbv9抗体的药物组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
CN102459643B (zh) 2009-06-25 2016-06-01 弗雷德哈钦森癌症研究中心 检测获得性免疫的方法
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514923B2 (en) 2017-12-25 2026-01-06 Joint Stock Company “Biocad” Methods of inhibiting the T cell receptor by administering a monoclonal antibody that binds TRBV9

Also Published As

Publication number Publication date
WO2020091635A3 (ru) 2020-10-22
JP2022532274A (ja) 2022-07-14
CO2021008218A2 (es) 2021-07-30
EP3907239A2 (en) 2021-11-10
PE20220217A1 (es) 2022-02-02
CA3124813A1 (en) 2020-07-02
JOP20210169B1 (ar) 2025-10-01
PH12021551532A1 (en) 2022-02-28
US20220112286A1 (en) 2022-04-14
ZA202104357B (en) 2022-09-28
RU2712251C1 (ru) 2020-01-27
CN114144432A (zh) 2022-03-04
MA53689A1 (fr) 2022-06-30
WO2020139175A3 (ru) 2020-10-29
WO2020091635A2 (ru) 2020-05-07
ECSP21046333A (es) 2021-07-30
CN113646333A (zh) 2021-11-12
PH12021551775A1 (en) 2022-05-23
KR102788029B1 (ko) 2025-03-31
US12227572B2 (en) 2025-02-18
MY205967A (en) 2024-11-21
JOP20210169A1 (ar) 2023-01-30
EA202191813A1 (ru) 2021-10-07
SG11202106975VA (en) 2021-07-29
IL284370A (en) 2021-08-31
KR20210119404A (ko) 2021-10-05
BR112021012555A2 (pt) 2021-09-14
CR20210354A (es) 2021-12-20
CO2021009689A2 (es) 2021-08-09
TW202039574A (zh) 2020-11-01
WO2020139175A2 (ru) 2020-07-02
CN113646333B (zh) 2025-04-08
MX2021007719A (es) 2022-03-25
AU2020204492A1 (en) 2021-08-12
CL2021001705A1 (es) 2022-01-28
EP3907239A4 (en) 2022-10-05
AR117734A1 (es) 2021-08-25
KR20220131489A (ko) 2022-09-28
MA53689B1 (fr) 2023-03-31

Similar Documents

Publication Publication Date Title
US12514923B2 (en) Methods of inhibiting the T cell receptor by administering a monoclonal antibody that binds TRBV9
US12227572B2 (en) Monoclonal antibodies against the beta chain region of human TRBV9
US12297269B2 (en) Monoclonal antibodies that bind specifically to human TRBV9
US12311031B2 (en) Antibodies specific to CD44
TWI914298B (zh) 特異性結合至人類Ｔ細胞受體之ＴＲＢＶ-９家族之β區的單株抗體及其使用之方法
TWI917314B (zh) 針對人類ＴＣＲ ＴＲＢＶ９第９家族之β鏈區的人類化抗體及其使用方法
OA20245A (en) Monoclonal antibodies that bind specifically to human TRBV9.
OA20246A (en) Monoclonal antibodies against the beta chain region of human TRBV9.
EA042982B1 (ru) Моноклональные антитела против участка бета-цепи trbv9 человека
HK40039968B (zh) 单克隆抗体及其使用方法
HK40039968A (en) Monoclonal antibodies and methods for using same
EA041880B1 (ru) Моноклональные антитела и способы их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210723